Released Aug 9, 2013, after the close
10-Q filed Aug 9, 2013, 40 days after period end · 0001390478-13-000010
Q2 2013 · 10-Q
Revenue$3.38M$3.38M ±0.0% vs Q2 2012+23.0% vs Q1 2013
Net Income$5.39M$5.39M N/M vs Q2 2012N/M vs Q1 2013
EPS Diluted-$0.11-$0.11 N/M vs Q2 2012N/M vs Q1 2013
Gross Profit$2,914,000±0.0%
Operating Income-$7,986,000—
Operating Cash Flowderived-$7,123,000N/M
Margins · derived
Gross margin86.2%±0.0 pt vs Q2 2012
Operating margin-236.1%
Net margin159.3%+622.4 pt vs Q2 2012
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2013 | Q2 2012 | Q2 2011 | Q2 2010 |
|---|---|---|---|---|
| Revenue | $3.38M | $3.38M | — | — |
| Net Income | $5.39M | -$15.66M | -$3.75M | -$2.14M |
| EPS Diluted | -$0.11 | -$0.03 | -$0.10 | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR